Prostate and Urologic Cancer Research Group

Programs and Projects

Prostate Cancer Clinical Trials - Roswell Park Cancer Institute

Agent: L-Selenomethionine
Contact: James Marshall, MD or Ian Thompson, MD
DCP Program Director: Joe Tangrea, MPH, PhD

The purpose of this study is to see if selenium can reduce the prevalence of prostate cancer in men with a pre-cancerous condition known as High Grade Prostatic Intraepithelial Neoplasia (HGPIN). Those taking part in the study will receive selenium for up to three years. The study is being conducted under the auspices of the Southwest Oncology Group for the NCI Cooperative Groups. The investigator is actively accruing participants to this trial.

[This is a phase 3 randomized double-blind placebo controlled cooperative intergroup trial of l-selenomethionine for the chemoprevention of prostate cancer in subjects with High Grade PIN. The primary endpoint is the period prevalence of biopsy detected prostate cancer at 3 years.]